₹2,400 crore and ₹4,500 crore in FY22 and FY23 and incremental net profit of ₹400 crore and ₹1,000 crore in FY22 and FY23 resulting in 17% and 40% earnings upgrade to our FY22 and FY23 earnings estimates," said analysts at Phillip Capital Institutional Equities in a note.
They expect Cadila to sell close to 83-150 million doses in FY22 and FY23, respectively, and assume a blended price of ₹300 per dose.
Meanwhile, the company also announced receiving approval for the launch of Tofacitinib extended-release tablets of 11 mg and 22 mg in the US.
The 22mg tablet will have a 180-day marketing exclusivity. Though the US market for Tofacitinib is currently more than $2 billion a year, extended-release tablets comprise half of this market, say